Literature DB >> 2985716

Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice.

C W Lutton, C J Gauntt.   

Abstract

A significant reduction in the number of virus-induced myocardial lesions was effected by administration of murine interferon beta (IFN-beta) or polyriboinosinic: polyribocytidylic acid copolymer (pI:pC) at -24, 0, or 24 h but not 72 h postinoculation (p.i.) of coxsackie-virus B3 (CVB3) to adolescent CD-1 mice. Inoculation of interferon at any of the four times did not reduce virus titers in heart tissues at three or seven days p.i., but inoculation of pI:pC at -24, 0, or 24 h p.i. significantly reduced virus titers. Administration of anti-murine IFN-beta at 72 h p.i. significantly reduced myocarditic lesion numbers. The results suggest that there are two identifiable times after CVB3 inoculation in which interferon may play a role in CVB3-induced myocarditis: a very early time (+/- 24 h of virus entry) in which the presence of interferon is beneficial to the animal and a later time (72 h p.i. of virus) in which absence of interferon is beneficial to the animal. In vitro studies on the effects of IFN-beta or anti-IFN-beta antiserum on replication of CVB3 in permissive primary cultures of murine neonatal skin fibroblasts show that this virus is sensitive to the antiviral action of interferon which is produced in infected cultures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985716     DOI: 10.1089/jir.1985.5.137

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  15 in total

Review 1.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

2.  In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis.

Authors:  E K Godeny; C J Gauntt
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

3.  Factors affecting the infection of the D variant of encephalomyocarditis virus in the B cells of C57BL/6J mice.

Authors:  K L Gaines; S G Kayes; G L Wilson
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

Review 4.  Role of natural killer cells in experimental murine myocarditis.

Authors:  C J Gauntt; E K Godeny; C W Lutton; G Fernandes
Journal:  Springer Semin Immunopathol       Date:  1989

Review 5.  Recognition and optimum management of myocarditis.

Authors:  A L Caforio; W J McKenna
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

6.  Coxsackievirus B3 infection alters plasma membrane of neonatal skin fibroblasts.

Authors:  C W Lutton; C J Gauntt
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

7.  The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury.

Authors:  Hideo Yasukawa; Toshitaka Yajima; Hervé Duplain; Mitsuo Iwatate; Masakuni Kido; Masahiko Hoshijima; Matthew D Weitzman; Tomoyuki Nakamura; Sarah Woodard; Dingding Xiong; Akihiko Yoshimura; Kenneth R Chien; Kirk U Knowlton
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 8.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

9.  Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity.

Authors:  Albert Heim; Sabine Weiss
Journal:  Med Microbiol Immunol       Date:  2003-09-12       Impact factor: 3.402

10.  The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis.

Authors:  Elizaveta Padalko; Dieter Nuyens; Armando De Palma; Erik Verbeken; Joeri L Aerts; Erik De Clercq; Peter Carmeliet; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.